medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 6

<< Back Next >>

Ann Hepatol 2015; 14 (6)

Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America

Gómez-Gutiérrez C, Chávez-Tapia NC, Ponciano-Rodríguez G, Uribe M, Méndez-Sánchez N

Language: English
References: 58
Page: 807-814
PDF size: 131.46 Kb.


ABSTRACT

Hepatitis C infection is a worldwide problem. The global prevalence of the hepatitis C virus (HCV) averages 3%. Moreover, its prevalence among patients undergoing haemodialysis (HD) varies worldwide, ranging from as low as 1% to up to 70%. There are few data on its prevalence in developing countries, and even less information is available on HD patients. A literature review revealed that the prevalence of HCV infection among patients undergoing HD in Latin America ranges from 4.2 to 83.9%, with most data stemming from Argentina, Brazil, Mexico, Peru, Chile, Venezuela and Cuba. The most common genotype was genotype 1, and subtype 1b was the most frequent. The risk factors associated with this condition were the duration of the HD treatment and blood transfusion before hepatitis C screening. In addition, HCV RNA detection by polymerase chain reaction is crucial for the diagnosis of HCV infection in HD patients. Trials using combinations of new oral antiviral drugs, such as sofosbuvir and combo (ombitasvir, paritaprevir, ritonavir and dasabuvir), should be the next step in the improvement of care among HD patients with HCV, because these therapeutic agents apparently do not require dose adjustment according to renal function. Finally, information on this subgroup of patients remains unavailable in some countries; therefore, additional studies are needed to determine the prevalence trend of HCV infection in these populations.


REFERENCES

  1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razav H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-S57.

  2. Kidney Disease: Improving Global Outcomes (KDIGO). KIDGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; 73: S1-S99.

  3. Mohd Hanafiah M, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.

  4. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87.

  5. Petruzziello A, Coppola N, Loquercio G, Marigliano S, Giordano M, Azzaro R, Diodato AM, et al. Distribution pattern of hepatitis C virus genotypes and correlation with viral load and risk factors in chronic positive patients. Intervirology 2014; 57: 311-8.

  6. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(s1): 74-81.

  7. Méndez-Sánchez N, Gutiérrez-Grobe Y, Kobashi-Margáin RA. Epidemiology of HCV infection in Latin America. Ann Hepatol 2010; 9(Suppl.): 27-9.

  8. Kershenobich D, Razavi HA, Sánchez-Avila JF, Bessone F, Coelho HS, Dagher L, Gonçales FL, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011; 31(S2): 18-29.

  9. Szabo SM, Bibby M, Yuan Y, Donato BM, Jiménez-Mendez R, Castańeda-Hernández G, Rodríguez-Torres M, et al. The epidemiologic burden of hepatitis C virus infection in Latin America. Ann Hepatol 2012; 11: 623-35.

  10. Méndez-Sánchez N, Paraná R, Cheinquer H, Alves de Mattos A, Gadano A, Silva M, Pessôa MG, et al. Latin American Association for the Study of the Liver recommendations on treatment of hepatitis C. Ann Hepatol 2014; 13(S2): S4-66.

  11. Marinaki S, Boletis JN, Sakellariou S, Delladetsima JK. Hepatitis C in hemodialysis patients. World J Hepatol 2015; 7: 548-58.

  12. Fabrizi F. Hepatitis C Virus Infection and Dialysis: 2012 Update. ISRN Nephrology 2012; 2013: 159760.

  13. Aguirre-Valadez J, García-Juárez I, Rincón R, Torre A. Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review. Ther Clin Risk Manag 2015; 11: 329-38.

  14. Rosa-Diez G, Gonzalez-Bedat M, Pecoits-Filho R, Marinovich S, Fernandez S, Lugon J, Poblete-Badal H, et al. Renal replacement therapy in Latin American end-stage renal disease. Clin Kidney J 2014; 7: 431-6.

  15. Fernandez JL, Valtuille R, Hidalgo A, del Pino N, Lef L, Rendo P. Hepatitis G virus infection in hemodialysis patients and its relationship with hepatitis C virus infection. Am J Nephrol 2000; 20: 380-4.

  16. Valtuille R, Moretto H, Lef L, Rendo P, Fernández JL. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up. Clin Nephrol 2002; 57: 371-5.

  17. Marinovich S. Registro Argentino de Diálisis Crónica San-Incucai 2012. Sociedad Argentina de Nefrología e Instituto Nacional Central Único Coordinador de Ablación e Implante [Argentine Chronic Dialysis Registry SAN-INCUCAI 2012].

  18. Gaite LA, Marciano S, Galdame OA, Gadano AC. Hepatitis C in Argentina: epidemiology and treatment. Hepat Med 2014; 6: 35-43.

  19. Callegaro FP, Kupski C, do Nascimento RC, Schmitt VM. Behavior of viral hepatitis C in patients from hemodialysis program from Hospital Săo Lucas da PUCRS. Scientia Medica 2006; 16: 3.

  20. Silva LK, Silva MB, Rodart IF, Lopes GB, Costa FQ, Melo ME, Gusmăo E, et al. Prevalence of hepatitis C virus (HCV) infection and HCV genotypes of hemodialysis patients in Salvador, Northeastern Brazil. Braz J Med Biol Res 2006; 39: 595-602.

  21. Oliveira-Penido JMM, Caiaffa WT, Guimarăes M, Caetano EVC, Carvalho AR. The seroprevalence of HCV in patients submitted to hemodialysis and health professionals in the State of Minas Gerais, southwest of Brazil. Nefrología 2008; 28: 178-85.

  22. Lemos LB, Perez RM, Lemos MM, Draibe SA, Silva IS, Silva AE, Ferraz ML, et al. Hepatitis C among predialysis patients: prevalence and characteristics in a large cohort of patients. Nephron Clin Pract 2008; 108: c135–140 [PMID: 18230916, DOI: 10.1159/000114452].

  23. Rodrigues de Freitas MJ, Alves A, Costa de Almeida MK, Silva A. Prevalence of hepatitis C virus infection and genotypes in patient with chronic kidney disease undergoing hemodialysis. J Med Virol 2013; 85: 1741-5.

  24. Vidales-Braz BM, Oliveira da Silva NM, Lobato R, Nunes F, Dias da Motal L. Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients. Virol J 2015; 12: 8.

  25. Karohl C, Ceratti Manfro R, Bergman Senger M, Saldanha Thomé F, Santos Gonçalves LF, Rigatto M, Prompt CA. Prevalęncia de anticorpos antivírus da hepatite C em pacientes em hemodiálise crônica de Porto Alegre. J Bras Nefrol 1995; 17: 40-6.

  26. Castillo L, Díaz P, Inostroza J, Espinoza R, Millaqueo L, Calderara M, Pinto A, et al. Prevalence of hepatitis C virus antibodies in chronic hemodialysis and kidney transplantation patients. Rev Med Chil 1993; 121: 1024-8.

  27. Rodríguez MI, Estay R, Soto JR, Wolff C, Plubins L, Child R, Armas R, et al. Prevalence of hepatitis C virus antibodies in a hemodialysis unit. Rev Med Chil 1993; 121: 152-5.

  28. Gonzalez R, Vollrath V, Pereira J, Covarrubias C, Vacarezza A, Chianale J. Prevalence of hepatitis C virus RNA in hemodialysis patients: comparison of four antibody assays. Nephron 1995; 69: 181-2.

  29. De los Rios R, Miyahira J, Colichon A, Cieza J. Prevalence of antihepatitis C antibodies in patients on chronic hemodialysis. Rev Med Hered 1997; 8: 67-71.

  30. Ballester JM, Rivero RA, Villaescusa R, Merlín JC, Arce AA, Castillo D, Lam RM, et al. Hepatitis C virus antibodies and other markers of blood-transfusion-transmitted infection in multi-transfused Cuban patients. J Clin Virol 2005; 34: S39-S46.

  31. Santana RR, Martínez Z, Martínez MT, Mato J. Hepatitis C virus present in hemodialysis units from Cuban western region. Rev Cub Meda 2009; 48: 28-35.

  32. Cabezas EP, Rodríguez RP, Falagán C, Zamora L, Fernández J. B and C hepatitis in patients with hemodialysis. MEDISAN 2010; 14: 141.

  33. Álvarez MM, Estenoz G, Garlobo DM. Epidemiologic risk factors of hepatitis C in hemodialyzed patients. MEDISAN 2010; 14: 464.

  34. Cuevas CC, Rodriguez A, Pedro R, Romero LI. Clinical and epidemiological characterization of patients with hepatitis C under hemodialysis and associated prognosis factors. MEDISAN 2012; 16: 669.

  35. Gane E, Kershenobich D, Seguin-Devaux C, Kristian P. Strategies to manage hepatitis C virus (HCV) infection disease burden-volume 2. J Viral Hepat 2015; 22(Suppl. 1): 46-73.

  36. Méndez-Sánchez N. The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico. Ann Hepatol 2012; 11: 550-1.

  37. González-Michaca L, Mercado A, Gamba G. Hepatitis C viral in patients with terminal chronic kidney failure. I. Prevalence. Rev Invest Clin 2000; 52: 246-54.

  38. González-Michaca L, Mercado A, Gamba G. Viral C hepatitis in patients with end stage renal disease. II. Viral genotypes. Rev Invest Clin 2000; 52: 491-6 [PMID: 11195176].

  39. Méndez-Sánchez N, Motola-Kuba D, Cha´vez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M. Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary- care hospital in Mexico City, Mexico. J Clin Microbiol 2004; 42: 4321-2.

  40. Cieza J, Pinare F, Hinostroza J, Estremadoyro L, Loza C. Factores de riesgo para infección por hepatitis C en dos unidades de diálisis de Lima-Perú. Rev Med Exp 2001; 18: 1-2.

  41. Méndez-Chacón P, Vidalón A, Vildosola H. Risk factors for hepatitis C in hemodialysis and its impact on the waiting list for kidney transplantation. Rev Gastroenterol Peru 2005; 25: 12-18.

  42. Valencia M, Cieza J. Factors associated with hepatitis C infection in patients with chronic hemodyalisis. Rev Gastroenterol Peru 2009; 29: 11-6.

  43. Beltrân M, Navas MC, De la Hoz F, Mercedes Muńoz M, Jaramillo S, Estrada C. Hepatitis C virus seroprevalence in multi-transfused patients in Colombia. J Clin Virol 2005; 34(Suppl. 2): S33-S38.

  44. López L, López P, Arago A, Rodríguez I, López J, Lima E, Insagaray J, et al. Risk factors for hepatitis B and C in multi-transfused patients in Uruguay. J Clin Virol 2005; 34(S2): S69-S74.

  45. Pujol FH, Ponce JG, Lema MG, Capriles F, Devesa M, Sirit F, Salazar M, et al. High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. J Clin Microbiol 1996; 34: 1633-6.

  46. Monsalve-Castillo F, Gómez-Gamboa L, Chacín-Bonilla L, Porto-Espinoza L, Costa-León L. Hepatitis C virus infection in hemodialysis patients in Maracaibo, Venezuela. Rev Inst Med Trop 2012; 54: 53-5.

  47. Chávez-Tapia NC, Ridruejo E, Alves de Mattos A, Bessone F. An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Ann Hepatol 2013; 12(S2): S3-S35.

  48. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, et al. Treatment of HCV with ABT-450/ r–ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-603.

  49. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007; 18: 1584-93.

  50. Sivapalasingam S, Malak SF, Sullivan JF, Lorch J, Sepkowitz KA. High prevalence of hepatitis C infection among patients receiving hemodialysis at an urban dialysis center. Infect Control Hosp Epidemiol 2002; 23: 319-24.

  51. Kelley VA, Everett-Kitchens J, Brannon LE, Connor K, Martinez EJ, Pearson TC, et al. Lack of seronegative hepatitis C virus infections in patients with chronic renal failure. Transplantation 2002; 74: 1473-5.

  52. Saab S, Martin P, Brezina M, Gitnick G, Yee HF. Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysis. Am J Kidney Dis 2001; 37: 308-15.

  53. Wreghitt TG. Blood-borne virus infections in dialysis unitsa review. Rev Med Virol 1999; 9: 101-9.

  54. Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002; 51: 429-33.

  55. Almroth G, Ekermo B, Mĺnsson AS, Svensson G, Widell A. Detection and prevention of hepatitis C in dialysis patients and renal transplant recipients. A long-term follow up (1989-January 1997). J Intern Med 2002; 251: 119-28.

  56. Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000; 61: 44-51.

  57. Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, Puro V, et al. Prevalence of patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001; 37: 1004-10.

  58. Lombardi M, Cerrai T, Geatti S, Negroni S, Pertusini L, Pegoraro M, Di Lullo G. Results of a national epidemiological investigation of HCV infection in dialysis patients. EDTNA ERCA J 1999; 25: 38-42.




2020     |     www.medigraphic.com